Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2019 May 1;129(5):2164. doi: 10.1172/JCI129277

Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis

Yoko Kojima, Kelly Downing, Ramendra Kundu, Clint Miller, Frederick Dewey, Hope Lancero, Uwe Raaz, Ljubica Perisic, Ulf Hedin, Eric Schadt, Lars Maegdefessel, Tom Quertermous, Nicholas J Leeper
PMCID: PMC6486328  PMID: 31042164

Original citation: J Clin Invest. 2014;124(3):1083–1097. https://doi.org/10.1172/JCI70391

Citation for this corrigendum: J Clin Invest. 2019;129(5):2164. https://doi.org/10.1172/JCI129277

During the assembly of Figure 6A and Supplemental Figure 4C, incorrect flow cytometry plots were included. The authors were able to provide the original data, and a corrected version of Figure 6A appears below. The online version of the supplemental data has been updated with the corrected version of Supplemental Figure 4C.

graphic file with name jci-129-129277-g269.jpg

The authors regret the error.

Version 1. 05/01/2019

Print issue publication

Footnotes


Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES